Skip to main content

Tweets

An 11 yr study of 2187 #RA pts Rx w/ 3068 treatment courses of biologics or JAki, found 275 new cases of #CKD . Compared w/ CTLA4-Ig, TNFi significantly lower CKD rates (HR 0.67), whiile JAKi higher CKD rates (HR 2.16). https://t.co/2Y5BuDzJRs https://t.co/e81lOhOMjX
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/uKc14y1fOm
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Myelitis Associated With Rheumatologic Dz studied in 41 pts (age 44yrs; 95%women). Dx: SLE (41%), Sjogrens (24%), UCTD (15%), Overlap (12%) w/ APL syndr. Half Dx were AQP4-IgG Ab+ (90% w/ extensive cord lesions), 7% MOGAD Ab+, 44% "double-seronegative" myelitis.… https://t.co/or6vuCZASs https://t.co/UxzSR6yJO5
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Overview of IL-23 inhibition for chronic inflammatory disease (partial read) from Lancet. Started with targeting the p40 subunit shared between IL-12 & IL-23A. Now we have specific inhibitors of the p19 protein of IL-23A. These agents are superior to TNFi in plaque… https://t.co/ud61WLgWs2 https://t.co/fQ7WhLyrsi
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Hydroxychloroquine effects studied in 30pts (23 RA, 7SLE). Results did not support that HCQ may reduce CV risk - Arterial stiffness was not affected by HCQ, HCQ modestly lowered HbA1c & lipids - yet HCQ has been shown to reduced CV risk in observational studies… https://t.co/n283HwvRm4 https://t.co/lQN342uevy
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
SGLT2 Inhibitor Protective Effects in Lupus Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D). https://t.co/I5ZrA9pXRU https://t.co/8U0ILPbMuN
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Swapping is Better than Cycling in Psoriatic Arthritis A real-world cohort study suggests that psoriatic arthritis failing to respond to TNF inhibitors (TNFi) may do better if they subsequently swap to an IL-17 inhibitor (IL-17i), rather than cycling to another TNFi.… https://t.co/VREQCx8TfI https://t.co/ylzYPHhedi
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Study of 168 patients with MDA5-positive Dermatomyositis finds that elevated IL-6 (≥ 13.41pg/m), lymphopenia (< 0.5 × 109) older age and high LDH predicted 6-month all-cause mortality in DM https://t.co/eHYrUtvsI9 https://t.co/SAy27Om2zu
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
Psoriasis pts w/ Arthralgia referred for Rheum Eval - 1419 referred pts, 8.4% (119) met at risk for PsA criteria, and 29% (35) developed PsA w/in 1yr. Predictors included +FHx PsO, Ultrasound synovitis or enthesopathy findings, & low tender joint count. https://t.co/Fxgiu6D72j https://t.co/b8dMCOC18F
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
GLP-1 Inhibitor Reduces Knee Osteoarthritis Pain Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a randomized trial showed. https://t.co/Ch5XYlq6lX

Dr. John Cush @RheumNow ( View Tweet )

1 year 3 months ago
Medscape 2024 Medical Student Experience Survey Medscape has published a survey overview of US Medical Student impressions and experiences, satisfaction, what they think of their education and how prepared are they for the USMLE (boards) and residency. https://t.co/WARsNeV3kJ https://t.co/Jaxw0CDsHD
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
EUSTAR study, 257 PSS pts. w/ 12+ mos F/U, skin Dz was 70% stable, 22% regressive, 7% progressive. Regressive skin change pts had significantly lower probability of FVC decline ≥10% & all-cause mortality (p=0.035) vs progressive patients https://t.co/3L9iVTPwKv https://t.co/NMuD8VW7Pu
Dr. John Cush @RheumNow ( View Tweet )
1 year 3 months ago
×